Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Petroni

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Endocrinology and Metabolism|June 18, 1999
Relative versus attributable risk of breast cancer from estrogen replacement therapyR J Santen, G R Petroni
Biometrics|June 1, 1995
Bivariate sequential designs for phase II trialsM R Conaway, G R Petroni
Biometrics|December 1, 1996
Designs for phase II trials allowing for a trade-off between response and toxicityM R Conaway, G R Petroni
Biometrics|March 1, 1994
A two-sample test for stochastic ordering with interval-censored dataG R Petroni, R A Wolfe
Urology|May 1, 1999
Urinary function after radical prostatectomy: a comparison of the retropubic and perineal approachesM Gray, G R Petroni, D Theodorescu
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2016
Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapiesN A Wages, C L Slingluff, G R Petroni
The Journal of Clinical Endocrinology and Metabolism|March 7, 2001
Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapyR J Santen, J Pinkerton, C McCartney, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancerT Krupski, G R Petroni, E A Bissonette, et al.
Urology|May 3, 2000
Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancerT Krupski, G R Petroni, E A Bissonette, et al.
Urology|May 3, 2000
Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostateT Krupski, G R Petroni, H F Frierson, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Endocrinology and Metabolism|June 18, 1999
Relative versus attributable risk of breast cancer from estrogen replacement therapyR J Santen, G R Petroni
Biometrics|June 1, 1995
Bivariate sequential designs for phase II trialsM R Conaway, G R Petroni
Biometrics|December 1, 1996
Designs for phase II trials allowing for a trade-off between response and toxicityM R Conaway, G R Petroni
Biometrics|March 1, 1994
A two-sample test for stochastic ordering with interval-censored dataG R Petroni, R A Wolfe
Urology|May 1, 1999
Urinary function after radical prostatectomy: a comparison of the retropubic and perineal approachesM Gray, G R Petroni, D Theodorescu
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 25, 2016
Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapiesN A Wages, C L Slingluff, G R Petroni
The Journal of Clinical Endocrinology and Metabolism|March 7, 2001
Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapyR J Santen, J Pinkerton, C McCartney, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Quality of life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancerT Krupski, G R Petroni, E A Bissonette, et al.
Urology|May 3, 2000
Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancerT Krupski, G R Petroni, E A Bissonette, et al.
Urology|May 3, 2000
Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostateT Krupski, G R Petroni, H F Frierson, et al.
Pageof 4